An interventional study of Multimodal AI-Based Pain Assessment in Chronic Pain, Cancer Pain and Neuropathic Pain, sponsored by Valentina Cerrone. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-26.
Sponsored by Valentina Cerrone · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Chronic Pain with a site in Italy — 19 open to participants now, 22 under way, none of them phase 3. Chronic Pain · Italy.
Among the 65 studies in Chronic Pain with a site in Italy, this one is the 12th largest by planned enrollment of the 40 interventional ones that give a count, is one of 10 that started in 2025, is one of 27 with no phase, reaches primary completion later than 8 of the 21 other live ones, and was the 54th registered.
3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.
Browse Chronic Pain studies →19 of the 65 studies in Chronic Pain with a site in Italy are open now. Recruiting first, the newest first:
Catholic University of the Sacred Heart · Sites in Italy, Sweden
Ages 18+
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · Sites in Italy
Ages 18–70
University of Bari · Sites in Italy
Ages 18+
Istituti Clinici Scientifici Maugeri SpA · Sites in Italy
Ages 18–75
Aurel Mengri · Sites in Italy
Ages 18–75
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 4 · Phase 4 5
First in 2003; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 60 across 2,388 interventional studies indexed under Chronic Pain.
Median enrollment 73 across the 40 interventional studies, 185 across the 25 observational. Of the 35 that completed or were terminated, 9 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 65 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Valentina Cerrone as lead sponsor.
Valentina Cerrone has 1 study filed under Chronic Pain — fewer than ten, so there is no comparison to draw.
4 of the studies in Chronic Pain with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07832929Aurel MengriGelified Radiopaque Ethanol (Absolute Gel) in Cervical Disc Herniation: an Observational Study in Routine Clinical Practice (GENESIS) | 2026-11-23 |
| NCT07432841Istituti Clinici Scientifici Maugeri SpAPersonalized High-Definition tDCS Protocols for Chronic Pain Treatment | 2027-02-28 |
| NCT07270588Catholic University of the Sacred HeartMobACT: An Internet-Based Intervention for Chronic Pain Patients | 2027-04-30 |
| NCT07677631University of BariEmotional Allodynia Questionnaire (AEQ) in Fibromyalgia (PEARL) | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 65 studies in Chronic Pain with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This single-center, non-profit, observational-interventional study aims to develop artificial intelligence (AI) models for the automatic assessment of chronic pain (APA - Automatic Pain Assessment). The study will enroll adult patients with chronic pain of various origins (oncologic and non-oncologic). Participants will undergo multidimensional evaluations that include clinical assessments, self-report questionnaires, bio-signal collection (e.g., EEG, EDA, HRV, GSR, PPG), and facial expression analysis via infrared thermography and video recordings.
The primary objective is to calibrate and test machine learning and deep learning models to recognize and predict the presence and severity of pain using multimodal data inputs. Secondary objectives include evaluating the effectiveness of pain treatments, assessing quality of life, and developing a standardized APA dataset for future research.
All data collection procedures are non-invasive and safe, and include tools like wearable sensors and standardized neurocognitive tests. The study is approved by the Italian Ethics Committee (Comitato Etico Territoriale Campania 2) and complies with GDPR and EU AI regulations.
This study, titled "Refining mUltiple artificial intelliGence strateGies for automatic pain assessment Investigations" (RUGGI), explores the integration of AI in chronic pain evaluation. Pain is a multidimensional and subjective experience, and conventional assessment methods often rely solely on self-reported scales. This introduces the risk of over- or under-treatment. To overcome this limitation, the study leverages multimodal data-including physiological signals, facial expressions, and linguistic analysis-to build models capable of objectively assessing pain intensity and characteristics.
The primary aim is to calibrate predictive models (e.g., Support Vector Machines, Random Forest, Convolutional Neural Networks, YOLO architectures, and MLPs) that can recognize pain patterns using supervised and unsupervised learning. Bio-signals (EEG, HRV, GSR, EMG), infrared thermography (HIRA system), and prosodic-linguistic features will be analyzed. Data will be collected during structured timepoints: baseline (rest), Stroop test execution, and follow-up.
Patients are recruited based on chronic pain diagnosis per IASP and ICD-11 criteria. Inclusion criteria include age ≥18 and informed consent. The study foresees a target enrollment of approximately 200 patients within 6 months. Data will be processed following a rigorous AI pipeline, including preprocessing, feature extraction, dimensionality reduction, and cross-validation (k-fold with grid search optimization). Outcome measures include the Area Under the Curve (AUC), sensitivity, specificity, F1 score, and model explainability (via SHAP, LIME).
Secondary outcomes include assessing patient-reported quality of life, evaluating analgesic strategies, and generating a public-use APA dataset. All procedures are compliant with Good Clinical Practice (GCP), GDPR, and EU Artificial Intelligence Act (Reg. 2024/1689). The study is conducted at the University Hospital "San Giovanni di Dio e Ruggi d'Aragona" in Salerno, Italy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with chronic pain will undergo a multimodal, non-invasive diagnostic assessment including self-reported pain questionnaires (NRS, DN-4, BPI), wearable biosignal acquisition (EEG, EMG, EDA, HRV), facial thermography using the HIRA system, video-based facial expression analysis, linguistic evaluation, and the Stroop Test. These data will be used to develop and validate machine learning models for automatic pain assessment.
Diagnostic Test: Multimodal AI-Based Pain Assessment
A non-invasive, multimodal diagnostic procedure combining self-reported pain scales (NRS, DN-4, BPI), wearable biosignal acquisition (EDA, EMG, HRV, EEG), facial thermography (HIRA system), video-based facial expression analysis, linguistic interview, and the Stroop Test. Data are used to train and validate machine learning models for automatic pain assessment in chronic pain patients.
Also known as: Automatic Pain Assessment, AI Pain Evaluation
Accuracy of AI models in classifying chronic pain
Accuracy will be calculated to evaluate how well supervised machine learning and deep learning models can correctly classify the presence of chronic pain using multimodal data (e.g., biosignals, facial thermography, video, and audio).
Time frame: From Day 0 (baseline) to Day 30 (follow-up)
Sensitivity of AI models in classifying chronic pain
Sensitivity (true positive rate) will be computed to determine the model's ability to correctly identify patients experiencing chronic pain. Unit of measure: Sensitivity (%)
Time frame: From Day 0 to Day 30
Specificity of AI models in classifying chronic pain
Specificity (true negative rate) will be computed to assess the model's ability to correctly identify patients who are not experiencing chronic pain. Unit of measure: Specificity (%)
Time frame: From Day 0 to Day 30
Precision of AI models in classifying chronic pain
Precision (positive predictive value) will be calculated to assess the proportion of correct positive predictions among all positive classifications. Unit of measure: Precision (%)
Time frame: From Day 0 to Day 30
F1-score of AI models in classifying chronic pain
F1-score, the harmonic mean of precision and sensitivity, will be used to assess overall model performance, especially in the presence of class imbalance. Unit of measure: F1-score (numeric value)
Time frame: From Day 0 to Day 30
AUC-ROC of AI models in classifying chronic pain
The area under the receiver operating characteristic curve (AUC-ROC) will be used to evaluate the model's ability to discriminate between pain and no-pain conditions across thresholds. Unit of measure: AUC-ROC (numeric value from 0 to 1)
Time frame: From Day 0 to Day 30
Change in Patient Global Impression of Change (PGIC) score
This outcome will measure patients' perceived improvement in their condition using the PGIC scale. Unit of measure: Score on a 7-point Likert scale (1 = No change to 7 = Very much improved)
Time frame: From Day 0 to Day 30
Change in Brief Pain Inventory (BPI) interference score
This outcome will measure how much pain interferes with daily functioning, using the BPI interference subscale. Unit of measure: Score from 0 (no interference) to 10 (complete interference)
Time frame: From Day 0 to Day 30
Correlation between analgesic treatments and pain intensity (NRS)
The outcome will assess the correlation between the type and frequency of analgesic treatments and changes in pain intensity, measured with the Numeric Rating Scale (NRS). Unit of measure: Pearson correlation coefficient (r), NRS scores from 0 to 10
Time frame: From Day 0 to Day 30
Creation of a structured multimodal dataset for AI-based pain research
A standardized and anonymized dataset will be developed from collected multimodal inputs (biosignals, thermography, facial videos, linguistic data, questionnaires) to enable future research. Unit of measure: Dataset availability (Yes/No)
Time frame: From Day 0 to Day 30
Plan to share: No — Individual participant data (IPD) will not be shared due to the sensitive nature of biometric and video-derived data, including facial thermography and audio recordings. Although all data are anonymized, there remains a potential risk of re-identification through multimodal signals. Additionally, no specific provisions for data sharing were included in the original informed consent approved by the ethics committee.
Started May 2025 (actual). Primary completion is estimated for Dec 2025, 7 months after the start.
Of 1,297 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 7 months is below that.
Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.